Oragenics, Inc. Chief Medical Officer, Dr. James Kelly, Joins the Medical Board of The Leigh Steinberg Foundation for Concussion, Traumatic Brain Injury, and Brain Health
24 Février 2025 - 2:30PM
Oragenics, Inc. (NYSE American: OGEN), a biotechnology company
advancing innovative treatments for concussion and brain-related
health conditions, proudly announces that its Chief Medical
Officer, Dr. James Kelly, has been appointed to the Medical Board
of The Leigh Steinberg Foundation for Concussion, Traumatic Brain
Injury, and Brain Health.
The Leigh Steinberg Foundation is dedicated to advancing brain
health by supporting research, raising awareness, and driving
actionable solutions for those affected by concussions and
traumatic brain injuries (TBI). Dr. Kelly’s appointment to the
Medical Board reflects his leadership in brain injury research and
treatment, reinforcing his influence in shaping the future of
concussion care.
As a globally recognized expert in TBI and neurological health,
Dr. Kelly has made pioneering contributions to the field. Before
joining Oragenics as Chief Medical Officer, he served as the
founding director of the National Intrepid Center of Excellence
(NICoE) at Walter Reed National Military Medical Center, where he
led advancements in diagnosing and treating brain injuries,
particularly for military personnel. His extensive experience also
includes working with athletes and individuals impacted by
concussions, positioning him as a key advocate for improved care
and research.
Janet Huffman, Interim Chief Executive Officer and Chief
Financial Officer of Oragenics, expressed the company’s enthusiasm
for Dr. Kelly’s appointment:
“We are thrilled to see Dr. Kelly recognized for his expertise
and dedication to brain health. His leadership at Oragenics has
been instrumental in driving the development of ONP-002, our novel
intranasal treatment for concussion. His involvement with The Leigh
Steinberg Foundation further aligns with our mission to advance
brain injury treatment and improve patient outcomes.”
Leigh Steinberg, founder of The Leigh Steinberg Foundation, also
welcomed Dr. Kelly’s appointment, highlighting the impact of his
expertise and Oragenics’ innovative work in concussion
treatment:
“Dr. James Kelly is a distinguished leader in traumatic brain
injury research and care, and we are honored to have him join our
Medical Board. His expertise and dedication to advancing brain
health align with our commitment to reshaping the narrative around
concussions and traumatic brain injuries. His leadership at
Oragenics in developing an intranasal treatment for concussions
represents a critical step toward turning breakthrough research
into tangible solutions. By leveraging innovative approaches to
treatment, we have the potential to enhance recovery and
accessibility for athletes, military personnel, and individuals
affected by brain injuries. We look forward to working with Dr.
Kelly as he helps guide Oragenics in its mission to prioritize
brain health and advance the future of concussion care.”
As a member of the Medical Board, Dr. Kelly will work alongside
leading researchers, medical professionals, and advocates to drive
forward initiatives in brain health education, innovative research,
and improved access to care. His work with Oragenics and the
foundation further underscores his dedication to revolutionizing
concussion management and enhancing patient outcomes.
“I am honored to join The Leigh Steinberg Foundation’s Medical
Board and contribute to its important mission of improving brain
health and concussion care,” said Dr. James Kelly. “With greater
awareness, research, and innovative treatment options, we can make
a meaningful difference in the lives of those affected by TBI.”
Investor Contact
Rich Cockrell404.736.3838ogen@cg.capital
About Oragenics, Inc.
Oragenics, Inc. (NASDAQ: OGEN) is a clinical-stage biotechnology
company focused on developing breakthrough treatments for
neurological disorders. The company’s lead asset, ONP-002, is an
innovative intranasal therapy designed to address the unmet medical
need in concussion treatment. Oragenics is committed to pioneering
new approaches in neuroscience to improve patient outcomes. For
more information, visit www.oragenics.com.
About The Leigh Steinberg Foundation
The Leigh Steinberg Foundation for Concussion, Traumatic Brain
Injury, and Brain Health is dedicated to advancing brain health
through advocacy, research, and real-world solutions. Founded by
legendary sports agent Leigh Steinberg, the foundation works to
raise awareness, support groundbreaking studies, and develop better
care strategies for individuals suffering from brain injuries,
particularly in sports and military communities.
Forward-Looking Statements
This communication contains “forward-looking statements” within
the meaning of the safe harbor provisions of the U.S. Private
Securities Litigation Reform Act of 1995. These forward-looking
statements are based on management’s beliefs and assumptions and
information currently available. The words “believe,” “expect,”
“anticipate,” “intend,” “estimate,” “project” and similar
expressions that do not relate solely to historical matters
identify forward-looking statements. Investors should be cautious
in relying on forward-looking statements because they are subject
to a variety of risks, uncertainties, and other factors that could
cause actual results to differ materially from those expressed in
any such forward-looking statements. These factors include, but are
not limited to, those described in our Form 10-K and other filings
with the U.S. Securities and Exchange Commission. All information
set forth in this press release is as of the date hereof. You
should consider these factors in evaluating the forward-looking
statements included in this press release and not place undue
reliance on such statements. We do not assume any obligation to
publicly provide revisions or updates to any forward-looking
statements, whether as a result of new information, future
developments or otherwise, circumstances should change, except as
otherwise required by law.
Oragenics (AMEX:OGEN)
Graphique Historique de l'Action
De Jan 2025 à Fév 2025
Oragenics (AMEX:OGEN)
Graphique Historique de l'Action
De Fév 2024 à Fév 2025